Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation models

International Journal of Antimicrobial Agents

Volumn 34, Issue 5, 2009, Pages 457-461

  Rubinchik, Evelina ^a   Dugourd, Dominique ^a   Algara, Teresa ^a   Pasetka, Christopher ^a   Friedland, H David ^a  

^a Migenix Inc   (United States)

Author keywords

Gram negative bacteria; Gram positive bacteria; Meticillin resistant S. aureus; Omiganan; Skin colonisation; Yeast

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE; MBI 226; OMIGANAN; PLACEBO; PSEUDOMONIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERICIDAL ACTIVITY; CANDIDA ALBICANS; CONTROLLED STUDY; DOSE RESPONSE; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; FEMALE; FUNGAL COLONIZATION; GUINEA PIG; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; SWINE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIA; CARRIER STATE; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; FEMALE; FUNGI; GUINEA PIGS; MICROBIAL VIABILITY; SKIN; SWINE; TREATMENT OUTCOME;

EID: 69949191216     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.05.003     Document Type: Article

References (15)

1. Fritsche T.R., Rhomberg P.R., Sader H.S., and Jones R.N. Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections. Antimicrob Agents Chemother 52 (2008) 1187-1189
2. Fritsche T.R., Rhomberg P.R., Sader H.S., and Jones R.N. Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections. J Antimicrob Chemother 61 (2008) 1092-1098
3. Sader H.S., Fedler K.A., Rennie R.P., Stevens S., and Jones R.N. Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity. Antimicrob Agents Chemother 48 (2004) 3112-3118
4. Pittet D., Tarara D., and Wenzel R.P. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 271 (1994) 1598-1601
5. Raad I. Intravascular-catheter-related infections. Lancet 351 (1998) 893-898
6. O'Grady N.P., Alexander M., Dellinger E.P., Gerberding J.L., Heard S.O., Maki D.G., et al. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control 30 (2002) 476-489
7. Mermel L.A. Prevention of intravascular catheter-related infections. Ann Intern Med 132 (2000) 391-402
8. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. Document M7-A7. Wayne, PA: CLSI; 2006.
9. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. 2nd ed. Document M27-A2. Wayne, PA: NCCLS; 2002.
10. Melo N.M., Dugourd D., and Castanho M.A.R.B. Omiganan pentahydrochloride in the front line of clinical applications of antimicrobial peptides. Recent Pat Antiinfect Drug Discov 1 (2006) 201-207
11. Hancock R.E.W., and Rozek A. Role of membranes in the activities of antimicrobial cationic peptides. FEMS Microbiol Lett 206 (2002) 143-149
12. Melo M.N., and Castanho M.A.R.B. Omiganan interaction with bacterial membranes and cell wall models. Assigning a biological role to saturation. Biochem Biophys Acta 1768 (2007) 1277-1290
13. Hoban D., Witwicki E., Zhanel G., Workman L., Clement J., Friedland H.D., et al. In-vitro resistance development of clinically relevant bacteria to omiganan pentahydrochloride. Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 13-17 September 2003; Chicago, IL (2003), ASM Press, Washington, DC Abstract E-2133
14. Oliveira L., Graham J., Lok C., MacFarlane S., and Zimmerman D. Risk factors for yeast superinfection in the treatment of suspected exit site infections: a case-control study. J Vasc Access 9 (2008) 35-38
15. Perez-Fontan M., Rosales M., Rodriguez-Carmona A., Falcon T.G., and Valdes F. Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 39 (2002) 337-341